Press Release (ePRNews.com) - WINCHESTER, England - Jan 21, 2016 - Winchester, UK – Exosect Ltd., a leading provider of enabling technologies, today announced that significant progress has been made with the European Annex I regulatory review of its dossier submission for its isolate of Beauveria bassiana.
Exosect’s Regulatory Affairs Officer, Sue Harris comments “We are currently reviewing the Draft Assessment Report (DAR) and we expect to have this completed by the end of this month. The regulatory dossier has now been distributed to member states therefore I am happy to say that we are on track to receive the Annex I approval by the end of 2016”.
Beauveria bassiana is an entomopathogenic fungus that grows naturally in soils throughout the world. It is unusual in that it offers dual control against both insects and plant pathogens and is also used as an animal feed additive.
Exosect has developed a precision delivery formulation for its isolate ofBeauveria bassiana using its proprietary formulation delivery platform Entostat, which optimises the delivery of fungal spores. So far the formulation has been developed for application to building structures (demonstrated in grain stores) and is currently being developed as an admixture (demonstrated in grain).
Exosect are currently seeking license partners for this technology.
Notes to editors
Entostat is an electrostatically charged micro-powder. A leading variant of Entostat is based on a carnauba wax blend that is chemically inert.
This variant of Entostat is sustainably harvested from the Brazilian Carnauba palm, Copernica martius (Palmae). Other variants include a range of natural and synthetic waxes and polymers.
Entostat is a non-hygroscopic electrostatic micro-powder that can be produced in a range of sizes and shapes. It can be formulated to microencapsulate synthetic active ingredients offering release retardation and to support biological active ingredients on its surface by electrostatic attraction.
Entostat readily gains an electrostatic charge, consequently it adheres to a range of surfaces including, grains and seeds, insects & animals, building fabrics.
It therefore has the potential to deliver active ingredients at a reduced application rate with equivalent or improved efficacy.
Entostat is a registered trademark of Exosect Ltd.
Exosect was launched in 2001 to develop proprietary platforms technologies, initially for agriculture.
The company has developed an in-depth knowledge and extensive patent portfolio of the platforms as targeted delivery mechanisms for a range of active ingredients, biological and synthetic.
Today, the technology is enabling our partners across a range of sectors to realise the efficient delivery of their active ingredients, helping them to overcome issues such as pest resistance, regulatory controls and residues within the food chain.
Exosect is focussed on the Agriculture, Public Health and Animal Health sectors. Source :